Stocklytics Platform
Asset logo for symbol UNCY
Unicycive Therapeutics
UNCY41
$0.43arrow_drop_up9.41%$0.03
Penny Stock
Asset logo for symbol UNCY
UNCY41

$0.43

arrow_drop_up9.41%

Performance History

Chart placeholder
Key Stats
Open$0.39
Prev. Close$0.39
EPS-0.36
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$41.97M
PE Ratio-
LOWHIGH
Day Range0.39
0.46
52 Week Range0.20
1.81
Ratios
Revenue-
EBITDA Margin %-
EPS-0.36

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Unicycive Therapeutics (UNCY)

Unicycive Therapeutics, Inc. (UNCY) is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of neurological disorders. The company's mission is to deliver transformative therapies that improve the lives of patients and their families. With a market cap of over $500 million, Unicycive Therapeutics is a rapidly growing player in the biotech industry.
One of the key factors that sets Unicycive Therapeutics apart from its competitors is its innovative approach to drug discovery and development. The company's proprietary platform utilizes a unique combination of computational biology, artificial intelligence, and machine learning to identify and validate novel drug targets. This allows Unicycive Therapeutics to rapidly identify promising drug candidates and move them through the development process more efficiently than traditional methods.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shalabh K. Gupta M.D., MPA
Headquarters
Los Altos
Employees
12
Exchange
NASDAQ
add Unicycive Therapeutics to watchlist

Keep an eye on Unicycive Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

Is Unicycive Therapeutics (UNCY) a growth stock?

Unicycive Therapeutics (UNCY) has shown an average price growth of 0.41% over the past three years. It has received a score of 63 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Unicycive Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Unicycive Therapeutics's (UNCY) price per share?

The current price per share for Unicycive Therapeutics (UNCY) is $0.47. The stock has seen a price change of $0.04 recently, indicating a 9.41% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Unicycive Therapeutics (UNCY)?

For Unicycive Therapeutics (UNCY), the 52-week high is $1.82, which is 322.79% from the current price. The 52-week low is $0.2, the current price is 112.87% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is Unicycive Therapeutics (UNCY) stock price performance year to date (YTD)?

As of the latest data, Unicycive Therapeutics (UNCY) has a year-to-date price change of -51.45%. Over the past month, the stock has experienced a price change of 14.7%. Over the last three months, the change has been -31.75%. Over the past six months, the figure is -69.06%.
help

Is Unicycive Therapeutics (UNCY) a profitable company?

Unicycive Therapeutics (UNCY) has a net income of -$30.54M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 57.93% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $391K. Operating income is noted at -$20.77M. Furthermore, the EBITDA is -$28.84M.
help

What is the market capitalization of Unicycive Therapeutics (UNCY)?

Unicycive Therapeutics (UNCY) has a market capitalization of $41.98M. The average daily trading volume is 1.27M, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media